Member Log-in

I forgot my password

Not a Member? Register

Continuing Pneumococcal Vaccination After Gavi Transition in Kenya at Full Price is Cost-effective and Could Save Thousands of Lives

This news release was originally published on EurekAlert. Below is an excerpt from the news release.

Co-led by the London School of Hygiene & Tropical Medicine and the KEMRI-Wellcome Trust Research Program, the Pneumococcal Conjugate Vaccine Impact Study estimated that continuing the vaccine beyond 2022 would prevent – in the first ten years – more than 100,000 children and adults from contracting pneumococcal disease and save the lives of 14,000 children and adults who would otherwise have died.

The cost per year of healthy life saved (US $153) was considerably less than Kenya’s annual gross domestic product (GDP) per person (US $1,790 in 2018), which meets – and far exceeds – the World Health Organization (WHO) GDP-related threshold for ‘very cost-effective’ health interventions.

The researchers say this study offers important evidence for policymakers at what is a crucial time for countries that have to decide whether to continue vaccine programs that have benefited from Gavi’s subsidy of the cost of vaccines once their economies grow and Gavi support diminishes.

You May Also Like

Update for Countries and Regional Partners Requesting Gavi Post-transition Support

In November 2017, the Gavi Board approved continued Gavi Alliance engagement with transitioned countries and a budget allocation of up to US$30m to support these countries until 2020. Support is being provided for technical assistance in key programmatic areas, including supply chain, LMC and data, paying special attention to innovative approaches and government commitment to … Continued

Transition to Program Budgeting in Health: Experience from Countries and Lessons Learned

WHO’s Department of Health Systems Governance and Financing is providing support to Ministries of Health in this transition process, with the following aims: 1) building the knowledge base on good practices in health budget reforms, including the development of an online health budget portal and country case studies; 2) providing technical support and guidance to … Continued

Donor Transitions From HIV Programs: What Is The Impact On Vulnerable Populations?

“Many middle-income countries are transitioning away from donor-funded health programs in a range of areas including immunization, maternal and child health, tuberculosis, malaria, and HIV. Unless these donor exits are managed well, they could imperil the sustainability of the remarkable gains that have been achieved over the past two decades in fighting killer infectious diseases and maternal … Continued

Choose a Language